Stockwinners Market Radar for May 08, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EDT ClearOne declares special dividend of $1.00 per share - The dividend is payable on May 31, 2023 to shareholders of record on May 22, 2023.

20:02 EDT Cathie Wood's ARK Investment bought 199.9K shares of Joby Aviation today

20:00 EDT Plains GP Holdings CEO buys $993.5K in common stock - In a regulatory filing, Plains GP Holdings disclosed that its CEO Willie Chiang bought 75K shares of common stock on May 8th in a total transaction size of $993.5K.

19:41 EDT PayPal CEO says still see many challenging issues - CEO Daniel Schulman says: "Even with the strong start, there remain many challenging issues to navigate as we look forward. Both the macroeconomic and geopolitical environments are complex and difficult to predict. In these times, the strong message I'm giving the PayPal team is to focus on the things we can control... For several years, we've been at the forefront of advanced forms of machine learning and AI to combat fraud and to implement our sophisticated risk management programs. With the new advances of generative AI, we will also be able to accelerate our productivity initiatives. We expect AI will enable us to meaningfully lower our costs for years to come. Furthermore, we believe that AI, combined with our unique scale and sets of data, will drive not only efficiencies, but will also drive a differentiated and unique set of value propositions for our merchants and consumers. So despite the fact that today's macro environment is difficult to forecast, we believe we are well positioned to deliver a strong year and enter next year poised to reap additional revenue streams from the investments we are making in our products while continuing to drive efficiencies and reduce our overall cost structure."

19:02 EDT Talos Energy cuts FY23 total production view to 24.1-25.9 MMBoe from 26.3-27.7 - Cuts FY23 average daily production view to 66-71 MBoe/d from 72-76.

18:35 EDT Wingstop CEO sells $1.02M in common stock - In a regulatory filing, Wingstop disclosed that its CEO Michael Skipworth sold 4.9K shares of common stock on May 9th in a total transaction size of $1.02M.

18:25 EDT Microsoft CMO Capossela sells 5,000 common shares - In a regulatory filing, Microsoft chief marketing officer Christopher Capossela disclosed the sale of 5,000 common shares of the company on May 5 at a price of $310.05 per share.

18:12 EDT Zions Bancorp director bought $480K in common stock - In a regulatory filing, Zions Bancorp disclosed that its director Claire Huange bought 24K shares of common stock on May 4th in a total transaction size of $480K.

18:02 EDT BurgerFi CEO Ian Baines retires - BurgerFi announced that Ian Baines has retired from his role of CEO, effective as of June 7, but, in lieu of any severance that would otherwise be payable under his employment agreement, has agreed to serve as an outside consultant to the company for the next 12-months following his resignation. The board has begun a comprehensive search for a new CEO.

17:58 EDT Hudbay Minerals backs FY23 production guidance 100K-128K - Reaffirmed full year 2023 consolidated production guidance of 100,000 to 128,000 tonnes of copper at a cash cost of 40c to 80c per pound and sustaining cash cost of $1.35 to $2.05 per pound as first quarter production was in line with quarterly cadence expectations.

17:53 EDT Cenovus Energy says roughly 85,000 BOE/d of production impacted by Alberta fires - Cenovus Energy provided an update on its Conventional production operations following ongoing wildfire activity in northern Alberta. Fires in the north-central region of the province have led the Government of Alberta to declare a state of emergency and a number of communities are under evacuation orders. With a focus on the safety of its people and integrity of its assets, on May 4, as a precaution, Cenovus began safely and methodically shutting in a number of producing Conventional fields and bringing down processing plants. Approximately 85,000 barrels of oil equivalent per day (BOE/d) of production, primarily dry gas, has been impacted in the company's Rainbow Lake, Kaybob-Edson, Elmworth-Wapiti and Clearwater operating areas. The overall wildfire situation is being closely monitored and the company's other assets, including its oil sands assets and Lloydminster complex, have not been impacted. The company isn't aware of any significant damage to date and will resume operations as soon as it's safe and permitted to do so. Cenovus's annual guidance range for 2023 is between 790,000 BOE/d and 810,000 BOE/d. The company is maintaining that guidance range and will continue to assess the duration of the production impact from the fires.

17:43 EDT Sachem Capital CEO John Villano appointed interim CFO - The company also announced that CEO John Villano was appointed interim CFO, effective immediately, following the departure of John Warch, the company's former chief financial officer, effective May 4. The reason for Warch's departure was not disclosed, but the company reported that it was not related to any disagreements with the company's accounting principles, practices or financial statement disclosures or its business operations. The company plans to initiate a search for a new chief financial officer.

17:40 EDT Russel Metals boosts quarterly dividend 5% to 40c per share - "As a result of our strong earnings profile, reduced cash flow volatility and strong capital structure, we have declared an increase in our quarterly dividend to 40c per share, payable on June 1 to shareholders of record at the close of business on May 30. This represents a 5% increase from the prior dividend and equates to an annualized dividend of $1.60 per share. Going forward, we plan to periodically review our dividend level for potential future modifications, by taking into account the prevailing market conditions, as well as our earnings profile, capital structure and alternative uses of capital," said the company in a statement.

17:15 EDT CPI Aerostructures gets manufacturing authorization from Raytheon Technologies - CPI Aerostructures (CVU) announced that Raytheon Technologies (RTX) authorized CPI Aero to begin manufacturing of pod structures and air management system components for the follow-on Low Rate Initial Production, or LRIP, phase 3 of the Next Generation Jammer Mid-Band, or NGJ-MB, program. The binding notification provides a maximum value of $32.6M. Raytheon Technologies (RTX) is designing and manufacturing NGJ-MB, a technologically superior, all-aspect, high-power offensive airborne electronic attack system able to achieve force-level spectrum superiority in modern Anti-Access/Area Denial environments. NGJ-MB enhances existing EA-18G and F/A-18E/F cooperation to increase kinetic engagement capacity. In June 2021, the NGJ-MB program reached Milestone C, indicating the system is ready for production. LRIP 1 was awarded July 2021, and an option for LRIP 2 was awarded December 2021. These awards enabled Raytheon Technologies to begin production on this critical capability to the U.S. Navy fleet and beyond. LRIP 3 includes the first four operational shipsets for the Royal Australian Air Force. There are two NGJ-MB pods per EA-18G aircraft. In February of this year, CPI Aero delivered an LRIP 1 Production Pod, the first of 20 planned deliveries in 2023. The contract announced today supports the LRIP 3 production deliveries.

17:06 EDT Hudson Pacific sees FY23 office same-store cash NOI up 1.00%-2.00% - Sees FY23 general and administrative expenses ($70,000)-($76,000); Interest expense ($204,000)-($214,000).

17:00 EDT 3D Systems to reduce headcount by 6% in restructuring initiative - 3D Systems announced the next phase of its multi-faceted restructuring initiative. This next evolution of restructuring will reduce headcount by approximately 6%, with the majority of reductions being made in corporate and business support functions which are predominantly located in the U.S. and Europe. The company expects this initiative to reduce operating expenses by approximately $4M-$6M in 2023 and to provide annualized savings between approximately $9M to $11M beginning in 2024. The company expects to incur cash charges in the range of $3.5M- $4.5M for severance-related costs related to this initiative during 2023. This reduction in operating costs is a result of investments made in improved business processes, rationalization of operations, improved operational efficiencies, and integration of acquisitions completed over the last two years. Having been announced today, the majority of these changes will be fully executed in the current quarter, with the remainder occurring in the second half of the year. In addition to this announcement, the company is providing further detail related to its previously announced initiative in February to improve manufacturing efficiencies in its European metal printer operations. These changes will include the insourcing of certain metal printer platforms into its Riom, France manufacturing facility, co-locating the manufacturing with the current engineering of these products. This approach should improve cycle time from development to production while improving operating efficiencies. The company is reaffirming the expectation for its European insourcing initiative to reduce operating expenses in 2023 by approximately $2.5-$3.5 and provide annualized savings of approximately $5.5M to $7M beginning in 2024. Commenting on these initiatives, 3D Systems' President and CEO, Jeffrey Graves said, "We are very proud to offer our customers the broadest range of additive manufacturing technologies in the industry, including both metal and polymer hardware systems, an enormous range of value-added materials, and the leading suite of software solutions in the industry, which we bring together through specific customer applications that enable rapid adoption in production environments. Building from this success, our challenge now is to leverage our scale to bring increased operating efficiencies to benefit our customers and shareholders. The actions we have announced over the course of this year are expected to generate a combined savings of approximately $6.5 - $9.5 million in 2023, and $14.5 million to $18.0 million in annualized savings beginning in 2024. These actions reflect our commitment to generating positive adjusted EBITDA this year, which we now expect to be over $2.0M for the full year 2023, with continued momentum in 2024 and beyond. These efforts are an extension of the ongoing work we began in late-2020 to streamline our operational footprint, focus our efforts, and better leverage our rich history in additive manufacturing. We continue to believe that right-sizing our cost structure and delivering positive adjusted EBITDA and free cash flow in 2023 will further improve 3D Systems' already strong balance sheet and enhance our flexibility to continue investing in the most critical areas of R&D, operations, customer service, and an efficient corporate infrastructure that is required to capitalize on the exciting market opportunities across our Industrial, Healthcare and emerging biologics markets. We believe this focused approach will unlock sustained value creation for our customers, shareholders, and society for years to come."

16:50 EDT Premier trading resumes

16:46 EDT Skyworks falls 8% to $96.99 after Q2 earnings miss, below-consensus guidance

16:41 EDT EverQuote withdraws previously provided FY23 guidance - Given the uncertainty of performance within the auto insurance industry and the exact timing of when carriers may restore their marketing budgets, the Company is withdrawing its previously provided full year 2023 guidance, said the company.

16:40 EDT Lucid Group falls 8% to $7.07 after Q1 results miss estimates

16:36 EDT IMV Inc. receives Nasdaq delisting notice - IMV Inc. announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act. The Company also announced on such date that it will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. Nasdaq informed the Company that trading in the Company's common shares would be suspended at the opening of business on May 11, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company's common shares from listing on the Nasdaq. IMV previously announced on March 31, 2023, its receipt of a letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price of US$1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2).

16:31 EDT Amcor announces intent to acquire Moda Systems, terms not disclosed - Amcor announced that it has signed a definitive agreement to acquire Moda Systems, a leading manufacturer of state-of-the-art, automated protein packaging machines. Based in New Zealand, privately-held Moda Systems designs, assembles and supports innovative, high-performance modular vacuum packaging solutions for the meat, poultry and dairy industries. The acquisition will complement Amcor's existing strength in film, positioning the company to offer an end-to-end packaging solution that encompasses primary packaging, equipment, on-site technical service and parts. The acquisition is subject to customary closing conditions and is expected to be completed in the June 2023 quarter.

16:29 EDT Kinder Morgan, Nestle announce commercial in-service of logistics hub project - Kinder Morgan (KMI) announced the commercial in-service of its renewable feedstock storage and logistics hub project with Neste (NSRGY), a provider of renewable diesel and sustainable aviation fuel. Neste will store a variety of raw materials like used cooking oil, which it collects from more than 80,000 restaurants across the United States, at Kinder Morgan's Harvey Terminal in Harvey, Louisiana to be used as feedstock in the production of renewable fuels and plastics. Enhancements to rail, truck and marine infrastructure have also been made at the facility to meet the modal flexibility requirements of Neste's feedstock supply chain. "We are proud to be taking a leading role with Neste in supporting a sustainable future," said KMI's President of Terminals John Schlosser. "This project is a great example of how Kinder Morgan's vast network of existing terminal infrastructure can be swiftly converted to meet the growing needs of the renewable fuels market in the U.S."

16:27 EDT Devon Energy expands stock repurchase program by 50% to $3B - "Given the substantial progress we have made with our buyback program, I am pleased to announce the board has expanded our share-repurchase authorization by 50% to $3B. This upsized program provides us additional runway to further compound per-share growth as we continue to execute on the tenets of our disciplined strategy," said CEO Rick Muncrief.

16:22 EDT SSR Mining acquire 40% interest in Hod Maden gold-copper development project - SSR Mining is pleased to announce that it has reached an agreement to acquire from Lidya Mines an up to 40% interest in, and operational control of, the Hod Maden gold-copper development project, located in northeastern Turkiye. Currently, Lidya Mines and Horizon Copper Corp. ( hold a 70% and 30% ownership interest, respectively, in Hod Maden. As consideration for the 40% ownership interest in Hod Maden, SSR Mining's payments include: $120 million upfront cash payment to acquire a 10% interest in the Project paid on closing of the Transaction on May 8, 2023; and $150 million in earn-in structured cash milestone payments to acquire an additional 30% interest in the Project, payable in accordance with an agreed upon schedule beginning at the start of construction and ending on the first anniversary of commercial production.

16:22 EDT Cohen & Steers reports preliminary AUM $80.9B as of April 30 - An increase of $1B from assets under management at March 31. The increase was due to market appreciation of $1.3B, partially offset by net outflows of $86M and distributions of $185M.

16:21 EDT Kingstone Companies estimates Q1 catastrophe losses $3.7M - Kingstone Companies announced that Kingstone Insurance Company, its wholly-owned subsidiary, estimates net pre-tax catastrophe losses for the first quarter of 2023 of $3.72M. Catastrophe losses for the quarter resulted from two events.

16:19 EDT Syndax reaffirms FY23 research and development expenses view $160M-$175M - Reaffirms FY23 total operating expenses view $225M-$240M.

16:18 EDT Syndax sees Q2 research and development expenses $38M-$43M - Sees Q2 total operating expenses $53M-$58M.

16:15 EDT Guardant Health names Ines Dahne-Steuber as chief operating officer - Guardant Health announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operating officer and the promotion of Darya Chudova to chief technology officer. Ines Dahne-Steuber brings over 20 years of leadership and strategic expertise in healthcare operations. Prior to joining Guardant Health, she served as senior vice president of operational excellence and president of Spectra Laboratories at Fresenius Medical Care North America. Spectra Laboratories performs 100 million clinical and environmental tests serving over 200,000 dialysis patients per year. Prior to Fresenius Medical Care, she served in various leadership roles at Quest Diagnostics, most recently as general manager for oncology and vice president of healthcare IT solutions. Ms. Dahne-Steuber earned her Bachelor of Arts and Master's degrees at Humboldt University in Berlin, Germany. Darya Chudova has been with Guardant Health for eight years, most recently serving as the senior vice president of technology. In this role, she initially focused on leading technical development of Guardant360 LDT and CDx products improving the precision, robustness and accessibility of Guardant's liquid biopsy tests.

16:12 EDT Theravance Biopharma reaffirms FY23 R&D expenses view $35M-$45M - Sees FY23 SG&A expense $45M-$55M. The Company reaffirms its expectation that it will generate non-GAAP profit in 2H 2023.

16:07 EDT FibroGen has option to acquire Fortis for $80M according to terms under pact - "The agreement with Fortis Therapeutics bolsters FibroGen's clinical pipeline in a capital-efficient manner, providing a product candidate with the potential to address a significant unmet medical need in oncology," said Enrique Conterno, Chief Executive Officer, FibroGen. "FOR46 is a natural fit with our R&D capabilities and expertise. The flexibility of the agreement gives us the opportunity to clinically develop FOR46, and ultimately acquire it as a Phase 3-ready asset, potentially delivering a therapy that may transform the treatment of patients with mCRPC and other CD46 expressing cancers." Under the terms of the agreement, there is no upfront consideration. FibroGen will conduct and fund future research, development, and manufacturing of FOR46 and PET46. During the four-year evaluation period, FibroGen has the option to acquire Fortis Therapeutics for $80M. In addition, Fortis is eligible to receive up to a total of $200M based on various regulatory approvals.

16:04 EDT Enanta reports positive topline results from phase 2 Sprint trial of EDP-235 - Enanta Pharmaceuticals "announced topline data from SPRINT, a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta's oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease. EDP-235 met the primary endpoint of the trial and was generally safe and well-tolerated. A dose-dependent improvement in symptoms was observed with EDP-235 treatment compared to placebo, which achieved statistical significance (pless than0.05) in the 400mg treatment group at multiple time points, starting as early as one day after the first dose. In a prespecified population consisting of patients enrolled within 3 days of symptom onset, a statistically significant improvement was observed with EDP-235 at 400mg at all time points. While no difference was observed in time to improvement of 14 targeted COVID-19 symptoms, an analysis of a subset of these symptoms showed a 2-day shorter time to improvement in patients receiving EDP-235 400mg who were enrolled within 3 days of symptom onset (pless than0.01). No effect on virologic endpoints as measured in the nose was detected due to the rapid viral decline in the placebo arm of this highly immunologically-experienced, standard risk population."

16:02 EDT Xencor sees ending 2023 with $425M-$475M in cash, cash equivalents - Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations through the end of 2025. The Company expects to end 2023 with between $425 million and $475 million in cash, cash equivalents, receivables and marketable debt securities.

15:31 EDT Pembina Pipeline provides updates on ongoing wildfires in Alberta, B.C. - Pembina Pipeline provided an update on the operational impacts of the ongoing wildfires in Alberta and British Columbia. "Wildfires in Alberta and B.C. have resulted in evacuation orders in several areas where Pembina has operations. Our priority is the health and safety of our people, impacted communities, and the environment. Pembina has accounted for all of our employees and contractors in the affected areas, and we are working to ensure they remain safe and receive the support they need. Our thoughts are with all impacted communities during this difficult time. We are evaluating current and anticipated operational impacts, and as part of our emergency response procedures we are working with all appropriate authorities to ensure necessary protocols are in place to mitigate risks. Assets currently shut down include the Saturn I and II gas plants at the Saturn Complex north of Hinton, Alberta, and the Duvernay Complex, west of Fox Creek, Alberta, with a combined processing capacity of 443 million cubic feet per day, net to Pembina. Various related pump stations, gathering systems and other supporting infrastructure are also shut down. The Wapiti Gas Plant, KA Plant and K3 Plant, as well as the Peace Pipeline system 20-inch line from Fox Creek, Alberta to Edmonton, Alberta, were temporarily shut down, however these assets have been safely restarted. To date, Pembina is not aware of any material damage to its assets. We continue to monitor this dynamic situation closely and as soon as it is safe to do so, operators will begin accessing the other impacted sites and implementing a phased restart plan for the impacted assets."

14:27 EDT Disney announces return of 'fan-favorite' dining plans - Disney shared "some more exciting news just in time for the launch of 2024 bookings for theme park tickets, Disney Resort hotel stays and packages at Walt Disney World on May 31." These updates include removing theme park reservation requirements for date-based tickets. Starting with park visits on Jan. 9, 2024, theme park reservations will no longer be required for date-based tickets. For other admission types, including non-dated tickets, theme park reservations may be required. The company also introduced "good-to-go days" for Annual Passholders and cast members. In 2024, Disney plans to offer select days on which its Annual Passholders and Disney cast members may visit Walt Disney World theme parks without needing a park reservation. Additionally, the company said it will be bringing back its "fan-favorite" Disney dining plans. Disney dining plans will be coming back as an option for those staying at Disney Resort hotels who purchase a vacation package starting with stays beginning Jan. 9, 2024, which will also open for bookings on May 31. Disney also said it will continue to provide extended park time to Disney Resort hotel guests and will simplify the Disney Genie+ experience. Reference Link

14:07 EDT Disney reports 'Guardians of the Galaxy 3' earns $289.3M in opening weekend - Marvel Studios' "Guardians of the Galaxy Vol. 3" topped the global box office in its opening weekend, earning $118.4M domestically and $170.9M internationally for a combined total of $289.3M, Disney (DIS) announced "It posted the highest IMAX global opening of 2023 - and, with $25 million, had the highest debut of the franchise. The film is now the 32nd consecutive Marvel Cinematic Universe film to debut No. 1 at the domestic box office. With Guardians of the Galaxy Vol. 3, MCU titles now account for six of the 12 movies that have opened to $100+ million since the start of the pandemic era," the company added. Reference Link

14:06 EDT Kiromic BioPharma trading halted, volatility trading pause

13:17 EDT Denny's announces appointment of Alex Williams as COO - Denny's announced the appointment of Alex Williams as Senior Vice President, Chief Operating Officer, reporting to Denny's President John Dillon. Williams will assume the position effective May 8. Dillon said: "Alex's role will be pivotal in taking Denny's to the next level-- ensuring that our world-class food and operational excellence continue to be the hallmark of the Denny's experience. I am thrilled to welcome Alex to the Denny's family."

13:05 EDT Tyler Technologies Chairman John Marr sold $4.2M in company shares - Chairman of Tyler Technologies, John Marr, disclosed in a regulatory filing that he had sold 11,000 shares of company stock at $382.70 per share between May 4 and May 5, for a total transaction amount of $4,209,744.

12:52 EDT B. Riley Financial co-CEO buys 25,000 common shares - In a regulatory filing, B. Riley Financial chairman and co-CEO Bryant Riley disclosed the acquisition of 25,000 common shares of the company on May 8 at a price of $34.6565 per share.

12:14 EDT Dish sees FY23 CapEx slightly lower than FY22 - Says outages did not materially affect Boost Mobile or Sling TV subscribers. Comments taken from Q1 earnings conference call.

12:00 EDT Tyson Foods falls -15.9% - Tyson Foods is down -15.9%, or -$9.64 to $51.05.

12:00 EDT Carvana rises 14.8% - Carvana is up 14.8%, or $1.33 to $10.29.

12:00 EDT MoneyLion rises 27.1% - MoneyLion is up 27.1%, or $3.56 to $16.70.

11:44 EDT United Airlines, Azul Airlines expand codeshare arrangements - Azul Brazilian Airlines and United Airlines announced an expansion to their codeshare agreement, making it easier for customers to travel to more cities in the United States. Travelers will be able to connect between Azul and United at Fort Lauderdale and Orlando to six new U.S. destinations: Chicago, Cleveland, Denver, San Francisco, Washington and Los Angeles. With the new codeshare flight options, customers will benefit from having a single ticket that includes both Azul and United-operated flights, as well as more convenience on their day of travel with one-stop check-in and baggage transfers. Tickets are already available on united.com and voeazul.com.br for flights starting May 10. This expanded agreement builds on United and Azul's existing codeshare routes from Houston and Newark.

11:07 EDT Ohmyhome Ltd trading halted, volatility trading pause

10:55 EDT Liquid Media adjourns Special Meeting following injunction - Liquid Media Group will be further adjourning the special meeting of shareholders previously scheduled for May 5, 2023, to rather be held on May 12, 2023 at 2:00pm PT at Suite 401, 750 West Pender Street, Vancouver, BC V6C 2T7 Canada. The former shareholders of the Company's subsidiary, Digital Cinema United, have obtained an injunction in the Supreme Court of British Columbia which has restrained the Company from proceeding with the Special Meeting pending the outcome of a dispute in respect of milestone shares issuable to the former DCU shareholders. The Company is assessing available options to resolve the disagreement and continue with the Special Meeting as proposed on May 12, 2023.

10:48 EDT Air Products to supply AP-SMR LNG process technology to Technip Energies - Air Products (APD) signed an agreement to supply its proprietary liquefied natural gas process technology and equipment to Technip Energies (THNPF) for the Xi'An LNG Emergency Reserve & Peak Regulation Project with Shaanxi LNG Reserves & Logistics Company, in ShaanXi Province, China. Air Products' technology will be vital for the liquefaction train producing 800,000 tons per year of LNG when the plant becomes operational. Under the agreement, Air Products will supply AP-SMR LNG Process technology, with proven performance for mid-scale LNG production, as well as the engineering, design and manufacturing of the coil wound main cryogenic heat exchanger for the liquefaction section of the plant. Air Products will also provide technical advisory services for the installation and commissioning, and performance testing when operational.

10:16 EDT Baxter trading resumes

10:08 EDT WWE reports 'record-breaking' Backlash in Puerto Rico - WWE announced that WWE Backlash, which emanated from the Coliseo de Puerto Rico Jose Miguel Agrelot in San Juan, Puerto Rico, became WWE's highest-grossing and most-viewed Backlash in company history. Viewership of Backlash saw a 28 percent increase versus the record set in 2022. The event, which featured Bad Bunny, the most-streamed music artist in the world, marked the largest gate ever for any WWE event held in Puerto Rico and the largest gate in the history of Backlash. More than 34,800 fans descended on San Juan, Puerto Rico, for back-to-back sellout nights of SmackDown and Backlash. It also marked the most social Backlash of all-time, led by over 40 million views of the San Juan Street Fight featuring Bad Bunny vs. Damien Priest. The hashtag #WWEBacklash, accompanied by a custom Bad Bunny emoji, trended No. 1 across the entire evening of sports. In addition, Backlash broke merchandise and sponsorship records. As the first-ever WWE event under the expanded partnership with Fanatics overseeing the on-site event retail experience, top-selling items included the WWE Backlash and LWO Puerto Rico t-shirts. Sponsorship revenue surpassed any Backlash event in history, breaking last year's record with a 98 percent year-on-year increase through partnerships with Netflix's FUBAR, Mike's Harder Lemonade and Xfinity.

10:06 EDT WWE reports 'record-breaking' Backlash in Puerto Rico - WWE announced that WWE Backlash, which emanated from the Coliseo de Puerto Rico Jose Miguel Agrelot in San Juan, Puerto Rico, became WWE's highest-grossing and most-viewed Backlash in company history. Viewership of Backlash saw a 28 percent increase versus the record set in 2022. The event, which featured Bad Bunny, the most-streamed music artist in the world, marked the largest gate ever for any WWE event held in Puerto Rico and the largest gate in the history of Backlash. More than 34,800 fans descended on San Juan, Puerto Rico, for back-to-back sellout nights of SmackDown and Backlash. It also marked the most social Backlash of all-time, led by over 40 million views of the San Juan Street Fight featuring Bad Bunny vs. Damien Priest. The hashtag #WWEBacklash, accompanied by a custom Bad Bunny emoji, trended No. 1 across the entire evening of sports. In addition, Backlash broke merchandise and sponsorship records. As the first-ever WWE event under the expanded partnership with Fanatics overseeing the on-site event retail experience, top-selling items included the WWE Backlash and LWO Puerto Rico t-shirts. Sponsorship revenue surpassed any Backlash event in history, breaking last year's record with a 98 percent year-on-year increase through partnerships with Netflix's FUBAR, Mike's Harder Lemonade and Xfinity.

10:01 EDT Applied Energetics appoints Stephen McCahon as CSO - Applied Energetics announced that Dr. Stephen McCahon has been appointed as Chief Science Officer, effective May 1, 2023. Dr. McCahon was an original co-founder of Applied Energetics, Inc., and in May of 2019, he returned to the company to serve as its Chief Scientist in a consulting role. Since that time, he has provided strategic direction to the Company's research and development activities in the areas of advanced optical technologies and USPL Directed Energy solutions.

10:00 EDT Genie Energy falls -8.7% - Genie Energy is down -8.7%, or -$1.34 to $14.00.

10:00 EDT Catalent falls -25.0% - Catalent is down -25.0%, or -$11.96 to $35.79.

10:00 EDT Braskem rises 18.9% - Braskem is up 18.9%, or $1.73 to $10.90.

09:49 EDT Baxter trading halted, news pending

09:47 EDT Tyson Foods falls -11.8% - Tyson Foods is down -11.8%, or -$7.15 to $53.54.

09:47 EDT Western Alliance rises 11.4% - Western Alliance is up 11.4%, or $3.09 to $30.25.

09:47 EDT Braskem rises 20.3% - Braskem is up 20.3%, or $1.86 to $11.03.

09:34 EDT ASP Isotopes enters multi-year supply agreement for Carbon-14 - ASP Isotopes announced that the Company has entered into a supply agreement for highly enriched Carbon-14 with RC-14, a Canadian company focused on the production and supply of Carbon-14. The Tolling Contract will involve the enrichment of Carbon-14 from feedstock supplied by RC-14 and CCNuclear and is subject to minimum volume commitments, which will be backed by a Bank Letter of Guarantee. The initial term of the contract is for 2 years, which can be extended to 10 years by mutual agreement. The Carbon-14 will be enriched in ASP Isotopes' Light Isotope Enrichment Facility in Pretoria, South Africa, which recently completed commissioning. The contract has specified a minimum annual revenue of approximately $2.5 Million and targeted annual revenue of approximately $3.8 Million. Production will commence when feedstock becomes available, which RC-14 expects during 2H 2023.

09:33 EDT Diana Shipping enters time charter contracts for m/v Santa Barbara, m/v Phaidra - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Smart Gain Shipping Co., Limited, for one of its Capesize dry bulk vessels, the m/v Santa Barbara. The gross charter rate is $21,250 per day, minus a 5% commission paid to third parties, for a period until minimum October 10, 2024 up to maximum December 10, 2024. The charter commenced on May 7, 2023. The "Santa Barbara" is a 179,426 dwt Capesize dry bulk vessel built in 2015. The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Aquavita International S.A., for one of its Post-Panamax dry bulk vessels, the m/v Phaidra. The gross charter rate is $12,250 per day, minus a 4.75% commission paid to third parties, for a period until minimum September 1, 2024 up to maximum November 15, 2024. The charter is expected to commence tomorrow. The "Phaidra" is a 87,146 dwt Post-Panamax dry bulk vessel built in 2013. The employments of "Santa Barbara" and "Phaidra" are anticipated to generate approximately $16.71 million of gross revenue for the minimum scheduled period of the time charters.

09:18 EDT Caribou Biosciences appoints Schuster to Scientific Advisory Board - Caribou Biosciences announced the appointment of Stephen Schuster, MD, to its scientific advisory board. Dr. Schuster is an expert in treating patients with lymphoma and developing novel treatments, including pioneering the development of chimeric antigen receptor-T cell therapies. Dr. Schuster is the Robert and Margarita Louis-Dreyfus Professor of Chronic Lymphocytic Leukemia and Lymphoma and the director of the Lymphoma Program and Lymphoma Translational Research at the Perelman School of Medicine at the University of Pennsylvania, with Penn Medicine's Abramson Cancer Center.

09:11 EDT Veeco receives multiple orders for LSA systems - Veeco Instruments announced that it received multiple orders for Laser Spike Annealing, LSA, systems from a world leading memory device manufacturer. Notably, these are Veeco's first systems for high volume manufacturing for DRAM devices. The company also announced it received multiple orders from its most recent advanced logic customer to support their production ramp. Veeco continues to execute its strategy of gaining market share through new applications wins. "We are proud to have our LSA platform selected for high volume manufacturing by leading memory and logic device manufacturers," commented Adrian Devasahayam, Ph.D., Veeco's Senior Vice President, Product Line Management. "Veeco's LSA system is widely acknowledged as the optimum annealing solution for low thermal-budget applications. As devices evolve at advanced nodes, precise annealing by our LSA platform is becoming more critical. The successful penetration in DRAM is expected to significantly increase our served available market."

09:10 EDT Lexaria Bioscience completes dosing in human clinical oral nicotine study - Lexaria Bioscience announces that dosing of the targeted 36 subjects in its human clinical oral nicotine study NIC-H22-1 has been completed. Human study NIC-H22-1 represents the culmination of several years of work performed by Lexaria on oral nicotine formulations as an alternative to vaping or smoking and may entice the more rapid commercial adoption and distribution of Lexaria's patented DehydraTECH absorption technology in an industry sorely lacking in oral uptake and performance optimizing innovation for many years.

09:08 EDT ProMIS Neurosciences announces FDA clearance of IND application for PMN310 - ProMIS Neurosciences announced that it has received clearance from the U.S. Food and Drug Administration, FDA, for its Investigational New Drug, IND, application for PMN310 for the treatment of AD. PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta that are believed to be a major driver of AD. "Receiving IND clearance for PMN310 marks an important corporate milestone as we continue towards our goal of delivering next-generation therapy to patients with Alzheimer's disease who have limited options to slow cognitive decline," said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences. "Our preclinical data demonstrated PMN310's greater selective binding to toxic oligomers compared to other Abeta-directed antibodies, which we believe supports the potential clinical profile of PMN310. We look forward to advancing PMN310 into clinical development and sharing what we learn from this innovative work."

09:07 EDT Amgen investors given opportunity to lead securities fraud class action - Law Offices of Howard G. Smith announced that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amgen. The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: the U.S. government claimed Amgen owed more than $3B in back taxes for tax years 2010, 2011, and 2012; the U.S. government claimed Amgen owed more than $5B in back taxes for tax years 2013, 2014, and 2015; the U.S. government would likely claim Amgen owed materially more to the U.S. government than investors had been led to believe for subsequent tax years for which Amgen had used the same profit allocation treatment between its U.S. and Puerto Rico operations; Amgen had not taken sufficient accruals to account for its outstanding tax liabilities; Amgen had failed to comply with rules and regulations regarding the preparation of its periodic SEC filings; and Amgen's refusal to pay taxes claimed by the U.S. government exposed Amgen to a substantial risk of severe financial penalties imposed by the IRS; and Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

09:05 EDT Galaxy Gaming launches Galaxy Operating System - Galaxy Gaming announced the launch of Galaxy Operating System, the next-generation game management system featuring innovative progressive jackpot options, striking LED sensors, and first-of-its kind digital tracking.

09:03 EDT Freddie Mac announces tender offer for any, all of certain STACR notes - Freddie Mac announced that it has commenced a fixed-price cash tender offer for the purchase of any and all of the STACR Notes beginning Monday, May 8, 2023. Certain of the series of Notes subject to the Offer were issued by the STACR trust. Freddie Mac is the holder of the owner certificate issued by each Trust and, as a result, the sole beneficial owner of each Trust. Freddie Mac has engaged BofA Securities, Inc. and Citigroup Global Markets Inc. as lead dealer managers and Academy Securities, Inc. as co-dealer manager for the Offer. Freddie Mac is offering to purchase any and all of the Notes listed. The applicable Total Consideration to be paid by Freddie Mac to holders that tender Notes accepted for purchase pursuant to the Offer will be calculated based on the original principal amount of such tendered and accepted Notes, the applicable factor, and the applicable Tender Offer Consideration identified in the table below, plus any accrued and unpaid interest under the applicable Debt Agreement or Indenture upon the terms and subject to the conditions set forth in the Offer to Purchase dated May 8, 2023 and related Notice of Guaranteed Delivery dated May 8, 2023. Capitalized terms used and not otherwise defined herein will have the meaning ascribed to such terms in the Offer to Purchase. The tender offer period will commence on Monday, May 8, 2023, and expire at 5 p.m. New York City time on Friday, May 12, 2023, unless extended. Holders must validly tender their Notes at or prior to the Expiration Time. Notes validly tendered may be withdrawn at any time at or prior to 5 p.m., New York City time, on Friday, May 12, 2023, unless extended by Freddie Mac, but not thereafter.

08:51 EDT CNS Pharmaceuticals appoints Bettina Cockroft to board of directors - CNS Pharmaceuticals has appointed Bettina M. Cockroft, M.D., M.B.A., to its Board of Directors as an independent director. Dr. Cockroft has served as the Senior Vice President and Chief Medical Officer of Sangamo Therapeutics, Inc. since 2019, overseeing all clinical development activities, clinical operations and drug safety.

08:49 EDT Virgin Galactic announces crew for return to space in late May - Virgin Galactic Holdings announced the mission specialists who will take part in the upcoming Unity 25 mission. Unity 25 is the final assessment of the full spaceflight system and astronaut experience ahead of the first commercial flight, 'Galactic 01', planned for late June. Please visit the Virgin Galactic website for further information.

08:48 EDT Brera completes acquisition of European football team Akademija Pandev - Brera Holdings announced it has completed its acquisition of the European first division football team Fudbalski Klub Akademija Pandev, Akademija Pandev, in North Macedonia, a country which has the right to participate in two major UEFA competitions. "This is an example of Brera Holdings implementing its international strategy to simultaneously pursue expansion and licensing of the Brera FC brand in Eastern Europe," said BREA CEO Sergio Scalpelli, who continued, "through the Akademija Pandev acquisition and Brera renaming we intend to enhance the team's performance, and ideally prepare players for the professional transfer market and obtain prizes related to participation rights in UEFA." In 2022, Akademija Pandev participated in qualifier matches of UEFA Conference League, the initial tier of the three UEFA competitions, that feature competition prizes from $250,000 to $15 million.

08:42 EDT ProPhase Labs hires Halpert as full-time consultant - ProPhase Labs announced that Dr. Matthew Halpert has been hired as a full-time consultant to drive the Company's key therapeutic and diagnostic programs forward which will comprise the backbone of ProPhase's efforts in both advanced cancer therapeutics and targeted cancer diagnostics. Dr. Halpert will assist with several ongoing programs at ProPhase BioPharma including Linebacker-1 initiatives as a cancer mono-therapy as well as to be developed as a potential co-therapy with multi-billion-dollar drugs like Doxorubicin.

08:40 EDT OSI Systems gets $9M order for airport security screening - OSI Systems announced that its Security division received an order for approximately $9M from an international aviation customer to supply a range of inspection equipment platforms. These include the RTT 110 explosive detection system for checked luggage, the Orion 920CT checkpoint baggage inspection system, and the Orion 920DX dual view X-ray checkpoint inspection system, among others. In addition to providing the equipment, the Company is also expected to provide multi-year maintenance services and support as part of this contract. OSI Systems' Chairman and CEO, Deepak Chopra, commented, "We are excited to support this customer and deploy our advanced inspection systems from our comprehensive portfolio and further strengthen our presence at international airports."

08:39 EDT Mirati Therapeutics partners with Sarah Cannon Research Institute - Mirati Therapeutics and Sarah Cannon Research Institute, one of the world's leading oncology research organizations conducting community-based clinical trials, announced a strategic partnership aimed at increasing diversity in clinical study recruitment practices. As part of this partnership, Mirati and SCRI will implement practices and programs focused on removing obstacles to clinical study participation, including expanding physician and patient education and increasing access to community-based clinical trials. Initiatives will be focused on reducing complexities associated with activating clinical trials thereby enabling a greater number of community practices to participate in research studies. SCRI's research network brings together more than 1,300 physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the U.S.

08:37 EDT Rocky Mountain announces retirement of Pope, SVP - Franchise Development - Rocky Mountain Chocolate Factory announced the retirement of Gregory Pope, Senior Vice President, SVP - Franchise Development, effective May 3, 2023. The Company has begun a nationwide search to secure a new franchise leader. Pope has agreed to serve as a consultant to the Company until December 31, 2023.

08:37 EDT Stagwell partnering with LexisNexis to power AI-driven PRophet platform - Stagwell's PRophet generative and predictive AI SaaS platform for PR professionals announced an alliance with LexisNexis, provider of news and business data, information and insights. This strategic alliance with LexisNexis aims to power PRophet's industry leading AI platform, which collectively brings access to upwards of 200,000 global news sources, including hyper local media, newsletters, trade publications and blogs. PRophet also announced the launch of "Powered by PRophet," a white-labeling option for PR agencies of all sizes. Customers can now customize the PRophet platform to their own specifications and go to market with an agency-branded platform.

08:36 EDT Surgalign releases HOLO AI Insights for neurovascular research - Surgalign Holdings announced the release of HOLO AI Insights for use in neurovascular research. HOLO AI Insights, initially launched in March 2023 for spine imaging, enables customers, partners, and clinical researchers to take advantage of the Company's HOLO artificial intelligence portfolio through a secure, highly scalable cloud platform for automated analysis of medical images. HOLO AI, Surgalign's portfolio of AI technology, utilizes convolutional neural network technology to automatically segment medical images, measure anatomic structures, automate pedicle screw planning, and perform other tasks. With this latest release, HOLO AI Insights has evolved to now address neurovascular research. This latest addition to the Company's portfolio, can analyze large sets of cranial MRI images, automatically identify 16 different structures, and aggregate the data for the user into configurable graphical and file formats. The insights generated by these results are believed to have multiple applications in population health, clinical research, and in the future, patient care.

08:35 EDT Clearmind Medicine appoints Joseph Tam to Scientific Advisory Board - Clearmind Medicine has appointed Professor Joseph Tam, D.M.D., Ph.D., to its Scientific Advisory Board. Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem. Prof. Tam is also a member of the Harvey M. Krueger Family Center for Nanoscience and Nanotechnology, served as president of the International Cannabinoid Research Society, and was a postdoctoral fellow at the National Institute on Alcohol Abuse and Alcoholism of the NIH.

08:33 EDT LM Funding signs contract with GIGA Corporation to host bitcoin mining machines - LM Funding America announced that the company has signed a new contract with GIGA Corporation to host 1,080 of its bitcoin mining machines, all of which are expected to be electrified and mining by May 31. LM Funding also announced it has acquired approximately 14,000 additional terahash in the form of 100 XP machines purchased at a discount from Bitmain Technologies Limited through its Pizza Day Raffle promotion These mining machines are expected to be electrified and mining by May 31.

08:32 EDT TD Holdings partners with ridesharing platform for digital logistics - TD Holdings has entered into a strategic cooperation agreement with Chongqing Call Me Travel Network, a shared ride platform that provides full-service solutions, to develop smart digital logistics and establish an industrial logistics system. Call Me agrees to provide the company with existing technology platforms and upstream and downstream resources in the new energy vehicle industry to facilitate the company's business development. The company agrees to introduce customer resources to Call Me to promote the platform's development. In addition, both parties mutually agree to establish a mechanism that promotes cooperation and negotiation. Each party will designate a supervisor to organize, coordinate, and drive efforts to encourage collaboration between the two parties.

08:23 EDT Bausch Health, Salix to deliver podium presentation at DDW 2023 - Bausch Health Companies and its gastroenterology business, Salix Pharmaceuticals will deliver a podium presentation of its research titled "Impact of Rifaximin Use During The 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy Hospitalization on Healthcare Utilization And Costs" during Digestive Disease Week 2023, which will be held virtually and in-person in Chicago, IL through Tuesday, May 9, 2023. The study led by Arun Jesudian, MD, Director of Inpatient Liver Services at NYPH/Weill Cornell, describes and compares healthcare resource utilization, including the rate of overt hepatic encephalopathy hospitalizations, and costs during the 30-day period following an OHE hospitalization among patients who are treated with Xifaxan versus those who are not. Results showed that initiation of Xifaxan after an OHE hospitalization resulted in reduced OHE-related hospitalizations in the 30-day period following an OHE hospitalization. Further, initiation of Xifaxan immediately upon discharge after the OHE hospitalization showed a high quality of care, with a lower rate of OHE-related hospitalizations. Additionally, reduced medical costs associated with fewer hospitalizations offset the increased pharmacy costs of Xifaxan. In addition, on Sunday, May 7, lead author Robert Wong, MD, MS Clinical Associate Professor of Medicine in the division of Gastroenterology and Hepatology at the Stanford University School of Medicine and Staff Physician in the Gastroenterology Section at the Veterans Affairs Palo Alto Healthcare System, presented a poster titled "Real-World Trends in The Prevalence of Cirrhosis and Rates of Overt Hepatic Encephalopathy Among Commercially Insured Adults in The United States From 2006-2020" that showed an increasing trend in the prevalence of diagnosed cirrhosis from 0.20% in 2006 to 0.45% in 2020. Among adults with cirrhosis, the rate of decompensation increased by 27% from 35.6% in 2006 to 45.2% in 2020 and the rate of OHE nearly doubled from 11.8% in 2006 to 21.4% in 2020. Based on the study findings, there were approximately 900,000 adults with cirrhosis, 450,000 with decompensated cirrhosis, and 200,000 with OHE in the US in 2020.

08:19 EDT Rhythm Pharmaceuticals announces Health Canada approval of IMCIVREE - Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome, BBS, or genetically-confirmed biallelic pro-opiomelanocortin, POMC, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance. "We are pleased to announce Health Canada's approval of IMCIVREE, marking a significant expansion of our footprint in North America and another important step forward in our efforts to deliver our precision medicine to people worldwide," said Jennifer Chien, Executive Vice President, Head of North America for Rhythm. "We will leverage insights from our experience with launches in the U.S. and Europe to support the strong team we have in Canada and look forward to making IMCIVREE commercially available in Canada in the months ahead."

08:17 EDT Enphase Energy expands IQ8 microinveter deployments in Mexico - Enphase Energy announced that installers of Enphase products in Mexico have seen growing deployments of residential solar energy systems powered by IQ8 Microinverters.

08:16 EDT LifeMD, HealthWarehouse.com partner in exclusive telehealth agreement - LifeMD announced that it has entered into an agreement to be the exclusive telehealth provider for HealthWarehouse.com. The partnership between the two companies will enable HealthWarehouse.com to offer virtual treatment to over one million existing patients and make available real-time consultations to potential new patients purchasing pharmacy products from their online health marketplace. LifeMD's 50-state affiliated medical group, composed of outstanding full-time doctors and nurse practitioners, provides convenient access to engage with a licensed medical provider and receive high-quality, personalized treatment. "LifeMD's mission is built on the premise that everyone should be able to access exceptional healthcare when and where they need it by removing the complexities that get between the patient and quality treatment," said Justin Schreiber, Chairman & CEO of LifeMD. "We are excited that this partnership with HealthWarehouse.com will empower an even larger population to easily access patient-first clinicians and receive, if appropriate, fairly priced prescription products."

08:15 EDT Onconova to present at ISID International Epidermolysis Bullosa Symposium - Onconova Therapeutics announced an upcoming presentation at the International Society of Investigative Dermatology International Epidermolysis Bullosa Symposium, which is being held in Osaka, Japan through May 9, 2023. The presentation will take place on May 9, 2023, at 1:00 p.m. Japan Standard Time. During the presentation, Onconova and the principal investigators will provide an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa. The Company previously announced that both of the program's evaluable participants achieved a complete clinical response of all cancerous skin lesions. Onconova plans to review these findings with regulators to determine the most expeditious path toward approval for rigosertib in RDEB-associated SCC.

08:13 EDT Kratos Defense announces deployment of multiple self-driving trucks - Kratos has multiple self-driving trucks deployed on the road across the United States supporting new deployment use cases and territories. Kratos deploys self-driving trucks to solve real-world workforce and safety issues of today burdening critical Transportation and Supply Chain operations. Since Kratos first adapted its U.S. Department of Defense driverless technologies to commercial markets in 2014, Kratos has continually expanded its driverless solutions and applications to the overall driverless trucking industry. The Kratos strategy for its commercial self-driving truck deployments has been methodically crafted in a progressive manner to capture a market comprised of millions of candidate vehicles. Starting with a driverless system design that is added to existing vehicles rather than only being available in newly purchased pre-configured vehicles, the Kratos technology can be applied to hundreds of millions of existing vehicles. This approach makes the application of driverless trucks achievable to effectively any municipality, organization, or company operating trucks today. Considering safety as the number one priority, Kratos has worked closely with highway authorities and stakeholders at the State and Federal level to coordinate the driverless technology implementation, define Operational Design Domains, and ensure regulatory and legislative compliance.

08:13 EDT Astrotech's 1st Detect secures purchase order for checkpoint security - Astrotech Corporation announced that its 1st Detect subsidiary has received a 17 unit order for its TRACER 1000 explosives trace detector, ETD. The systems will be deployed in Europe with deliveries scheduled to be fulfilled over the remainder of this calendar year. The company expects this sale will expand 1st Detect's footprint to 22 sites across 14 countries in Europe and Asia. "We're excited to extend our reach into more checkpoints throughout the world. Based on our near-zero false alarm rate, we believe that the TRACER 1000 improves checkpoint efficiency and passenger throughput by reducing the need for time-consuming and invasive secondary screenings that costs airports millions in lost merchandise and food sales," said Thomas B. Pickens III, Chairman and Chief Executive Officer of 1st Detect. The Astrotech Mass Spectrometer Technology powers the breakthrough TRACER 1000, the first certified ETD to use mass spectrometry. The TRACER 1000 is a rugged, fast, small, and easy to use mass spectrometer with near-zero false alarms. The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security.

08:11 EDT INmune Bio announces FDA clearance of IND application for INKmune - INmune Bio announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application for INKmune, a novel natural killer cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer. The Company believes this is the first NK immunotherapy trial in men with mCRPC, which affects more than 80,000 men in the U.S. The trial is expected to enroll the first of 30 patients in the second half of 2023. It will be opened at 4 more clinical study sites, with a goal to determine short and long-term safety of INKmune, demonstrate the ability of INKmune to control prostate cancer tumor burden, and identify a dose of INKmune to be used in a future blinded randomized pivotal trial. The principal investigator of the clinical trial is Prof. Matt Rettig MD, Professor of Medicine and Urology, Medical Director of the Prostate Cancer Program at the David Geffen School of Medicine at UCLA and member of the Jonsson Comprehensive Cancer. Prof. Rettig is a consultant to INmune Bio.

08:09 EDT Viridian Therapeutics partners with Enable Injections - Viridian Therapeutics announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse innovative wearable drug delivery system for volumes of up to 25mL.

08:06 EDT NewAmsterdam announces upcoming milestones - NewAmsterdam currently expects to achieve the following upcoming milestones: Present full data from the Phase 2 ROSE2 clinical trial testing the combination of obicetrapib and ezetimibe at the NLA Scientific Sessions, June 1-4, 2023 in Atlanta, GA. Complete enrollment of the Phase 3 BROADWAY trial for obicetrapib monotherapy in mid-2023 and announce topline data in the second half of 2024. Announce topline data from the Phase 2a trial evaluating obicetrapib in ApoE4-carrying patients with early Alzheimer's disease in the second half of 2023. Announce topline results from the Phase 2 obicetrapib monotherapy dose-finding trial in Japanese patients in the second half of 2023. Select formulation for Phase 3 fixed-dose combination of obicetrapib and ezetimibe in the second half of 2023. Complete enrollment in the Phase 3 PREVAIL trial for obicetrapib monotherapy in the first quarter of 2024 and announce topline data in the second half of 2026. Announce topline data from Phase 3 BROOKLYN trial for obicetrapib monotherapy in the second half of 2024.

08:05 EDT Infinera achieves 61.3 Tbps data transmission on 1,240 km intercity link - Infinera announced the completion of a simulated intercity network trial for Telstra InfraCo's intercity fiber project in Australia. The trial delivered a leading-edge 61.3 terabits per second of unregenerated data transmission capacity on a fiber pair over the equivalent of 1,240 route kilometers between Melbourne and Sydney. The network trial was implemented using Infinera's 800G-capable ICE6 coherent solution and Corning Incorporated's SMF-28(R) ULL fiber with advanced bend, demonstrating the high-performance capability of the express network, which is part of the intercity fiber network Telstra InfraCo is building across Australia. The trial was performed with real-world configurations, including 1,240 kilometers of ultra-low-loss fiber simulating one of Telstra InfraCo's planned express Melbourne-Sydney routes. Infinera performed an in-service, non-traffic-impacting upgrade from C-band to combined C-band plus L-band as part of the capacity expansion process. With Infinera's ICE6 and Corning's optical fiber, Telstra InfraCo achieved 61.3 Tbps total capacity with 6.2 milliseconds latency across the combined C-band and L-band, with wavelengths up to 700 Gbps.

08:05 EDT Hilton Grand Vacations announces new $500M stock repurchase plan - Hilton Grand Vacations announces its Board of Directors approved a two-year share repurchase plan authorizing the Company to repurchase up to an aggregate of $500M of its outstanding shares of common stock. The new repurchase plan will commence once the existing two-year repurchase program, which was approved by the Board of Directors in May 2022 for $500M, is fully completed. As of April 30, the Company had approximately $83M remaining under the prior repurchase program. "I'm pleased to announce that our Board of Directors has authorized a new $500 million, two-year share repurchase plan," said Dan Mathewes, senior executive vice president and CFO at Hilton Grand Vacations. "This new plan underscores our continued commitment to delivering long-term value to our shareholders through capital returns and reflects confidence in our cash flow trajectory and balance sheet strength."

08:04 EDT Eyenovia announces FDA approval of Mydcombi - Eyenovia announced that the U.S. Food and Drug Administration has approved Mydcombi 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first approved fixed dose combination of tropicamide and phenylephrine in the United States and also the first product using Eyenovia's proprietary Optejet device to be approved by any regulatory authority.

08:01 EDT Recursion Pharmaceuticals enters agreements to acquire Cyclica, Valence - Recursion signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence. Cyclica, headquartered in Toronto, has built two highly differentiated products in the digital chemistry space which will be integrated into the RecursionOS. MatchMaker is an AI-enabled deep learning engine that predicts the polypharmacology of small molecules as the foundation for small molecule drug discovery. It is able to generalize across the proteome and uses both AlphaFold2 structures and homology models. POEM is a unique similarity-based property prediction model. In contrast to other AI prediction models, POEM uses multiple types of molecular fingerprints to describe molecules, providing a much richer measure of similarity that leads to greater accuracy. Valence, headquartered in Montreal at Mila, the world's largest deep learning research institute, is committed to unlocking the full potential of deep learning in the drug discovery process. The company has pioneered the application of low-data learning in drug design, unlocking the ability to design differentiated small molecules with improved properties and function from datasets too small, sparse, or noisy for traditional deep learning methods. Valence has an unparalleled track record of innovation in molecular machine learning, including best-in-class methods for AI-enabled structural biology, generative chemistry, and multi-parametric optimization, ultimately enabling the design of best-in-class or first-in-class chemistry against challenging biology. Joining forces with Recursion's Montreal deep learning research office, Valence will become an artificial intelligence and machine learning research center to be led by Daniel Cohen with continued advisory from Yoshua Bengio. Recursion has entered into agreements to acquire Cyclica for a purchase price of $40 million and Valence for a purchase price of $47.5 million, in each case subject to customary closing and post-closing purchase price adjustments. The purchase price in the acquisitions will be payable in the form of shares of Recursion Class A common stock, shares of a subsidiary of Recursion exchangeable for shares of Recursion's Class A common stock and the assumption of certain outstanding Valence and Cyclica options. In certain limited circumstances, Recursion may pay nominal cash consideration to Valence and Cyclica shareholders in lieu of such exchangeable shares or Recursion Class A common stock. Recursion expects no material change to its cash runway as a result of these acquisitions. Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

07:37 EDT Marathon Gold announces 2023 board nominees, provides details of upcoming AGM - Marathon Gold provides details of its 2023 annual general and special meeting of shareholders to be held at Signal Hill Campus in St. John's, Newfoundland and Labrador. George Faught, Chairperson of the Board of Directors of Marathon, has decided not to run for re-election at the AGM so that his position on the Board is available to a new director whose election would result in the Corporation satisfying its gender diversity target of 30%. The remaining current directors on the Board, being Douglas Bache, Cathy Bennett, Jim Gowans, Julian Kemp, Peter MacPhail, Matt Manson and Janice Stairs, have all agreed to stand for re-election. Faught was first appointed to the Board of Directors in 2010 and has served as its Chairperson since 2011. It is currently proposed that Peter MacPhail would be appointed the new independent Chairperson of the Board, subject to his re-election at the AGM and subsequent approval by the Board. Marathon is pleased to announce that Teodora Dechev has been nominated by the Corporation to stand for election as a director at the AGM. Since 2009 she has served as President, CEO and Director of Mundoro Capital

07:36 EDT Ideanomics secures two contracts valued at more than $6M - Ideanomics is pleased to announce that its subsidiary US Hybrid has secured two large follow-on orders for electric propulsion systems that, separately, will be used in Department of Defense projects and to power specialty vehicles. These two orders, valued at more than $6M, are part of US Hybrid's robust customer pipeline through the next 12-18 months, which is expected to generate more than $50M in sales.

07:35 EDT Marker Therapeutics appoints Monic Stuart as Chief Medical Officer - Marker Therapeutics (MRKR) announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer. Dr. Stuart brings more than 20 years of experience as a clinician-scientist and drug developer to Marker Therapeutics where she will be responsible for advancing the development of multi-tumor associated antigen-specific T cell product pipeline, including the ongoing MT-401 Phase 2 ARTEMIS clinical study and Phase 1 clinical study of MT-601. Dr. Stuart previously served as Vice President of Clinical Development at Geron Corporation (GERN).

07:35 EDT Ironwood announces more detailed data on linaclotide study at DDW meeting - Ironwood Pharmaceuticals presented findings during the 2023 Digestive Disease Week, DDW, meeting from a Phase III clinical trial on the potential of linaclotide for children and adolescents ages 6-17 years-old with functional constipation. Ironwood had previously announced topline data from this study in September 2022. The presented data at DDW, which provided a more detailed description of the trial results, were announced during an oral presentation titled Efficacy and Safety of Linaclotide in Treating Functional Constipation in Pediatric Patients Aged 6-17 Years: A Phase 3, Pivotal, Randomized, Placebo-Controlled Trial , which highlighted that linaclotide 72 mcg met primary and secondary endpoints for increased frequency of spontaneous bowel movements, SBM, and improvement in stool consistency in this patient population. Linaclotide was generally well-tolerated and exhibited a safety profile consistent with a prior pediatric Phase II study in functional constipation. "Functional constipation is one of the most common complaints patients bring to their pediatricians and pediatric gastroenterologists, yet we have no approved prescription therapies to offer to our young patients," said Jeffrey S. Hyams, M.D., Head, Division of Digestive Diseases, Hepatology, and Nutrition, Connecticut Children's Medical Center, Professor of Pediatrics, University of Connecticut School of Medicine. "These results are significant because they show the potential of linaclotide in addressing bothersome symptoms for patients ages 6-17 years-old with this condition."

07:34 EDT Nephros announces CEO Astor to retire, Robert Banks to succeed - Nephros announced that Andy Astor, President and Chief Executive Officer, will retire in the coming months, and that Robert Banks will be named President and Chief Executive Officer effective on the first business day after the filing of Nephros' Form 10-Q for the quarter ended March 31, 2023. Banks is also expected to be appointed to the Nephros Board of Directors. Andy Astor will remain with Nephros as an advisor to Banks and as interim Chief Financial Officer, CFO, while a search is conducted for a permanent CFO. As part of the transition, Astor will step down from the board of directors. Most recently, Banks was Vice President of Global Strategic Accounts at Danfoss Power Solutions.

07:24 EDT Aravive to host virtual KOL event on batiraxcept - Aravive announced it will host a virtual Key Opinion Leader, KOL, event on its late-stage oncology asset, batiraxcept, on Wednesday, May 24, 2023 at 1:00pm ET. The event will feature oncology experts Katherine Fuh, MD, PhD, who will discuss batiraxcept as a potential treatment for ovarian cancer, and Katy Beckermann, MD, PhD, who will provide an overview of batiraxcept as a promising treatment for kidney cancer. The Aravive leadership team will provide a company update and overview of the commercial opportunity and future directions. Batiraxcept has been granted Fast Track Designation by the U.S. FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation for pancreatic ductal adenocarcinoma. Batiraxcept has been granted Orphan Drug Designation by the European Commission for platinum-resistant recurrent ovarian cancer.

07:22 EDT CureVac doses first patient in Phase 1/2 study of influenza vaccine candidates - CureVac announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK. The tested multivalent vaccine candidates address all four WHO-recommended flu strains. The combined Phase 1/2 study will evaluate mRNA-based, modified, multivalent influenza vaccine candidates for safety, reactogenicity and immune responses. The first Phase 1 dose selection part is being conducted in the U.S. and Belgium and will feature a licensed flu comparator vaccine. As previously reported, in CureVac and GSK's ongoing Phase 1 trial in older and younger adults of a monovalent, modified mRNA seasonal flu vaccine candidate, preliminary data showed a favorable tolerability profile and no concerning safety signals. Preliminary immunogenicity data indicated strong hemagglutinin inhibition immune responses in line with a licensed flu comparator vaccine beginning at the lowest tested dose.

07:19 EDT AstraZeneca reports Koselugo approved in China for inoperable PN in NF1 patients - Koselugo has been approved in China by the National Medical Products Administration for the treatment of symptomatic, inoperable plexiform neurofibromas, or PN, in paediatric patients with neurofibromatosis type 1, or NF1, aged three years and above, AstraZeneca announced. Reference Link

07:19 EDT Asante Gold grants exclusivity period to Fujairah Holding - Asante Gold entered into a confidentiality agreement with Fujairah Holding in connection with the previously-disclosed, unsolicited, non-binding and conditional expression of interest to acquire all of the Company's issued and outstanding common shares not held by Fujairah. The Company has granted Fujairah an exclusivity period that expires on May 15, 2023. Fujairah has indicated to the Company that it is willing to engage in financing discussions with the Company. The Company confirms that entering into the confidentiality agreement and grant of exclusivity does not constitute Board support of the Non-Binding Expression of Interest. The Company has no indication as to Fujairah's intentions to submit any additional binding or non-binding proposal with respect to the acquisition of the Company's common shares not held by Fujairah or any potential financing to be provided by Fujairah. Any such proposals, if received, would be reviewed by the Company, in consultation with the Company's financial and legal advisors. The Company does not undertake any obligation to provide any updates with respect to the Non-Binding Expression of Interest or any other proposals, except as required under applicable law.

07:17 EDT Arko Corp. extends Oak Street commitment for up to $1.5B - ARKO Corp. announced two separate agreements that enhance the Company's dealmaking flexibility and long-term growth strategy. On May 2, 2023, ARKO subsidiary, GPM Investments, LLC, together with affiliates of Oak Street, a division of Blue Owl Capital. entered into a third amendment to the program agreement with Oak Street. This amendment extends the term of the Program Agreement and provides for an aggregate up to $1.5 billion of capacity from the date the amendment was signed through September 30, 2024. This $1.5 billion is in addition to the funding for the previously announced acquisition of WTG Fuels Holdings LLC, which is expected to close in the second quarter. Additionally, ARKO subsidiary, GPM Petroleum LP, renewed and extended its revolving credit facility with a syndicate of banks led by Capital One, National Association. The credit line was increased by $300 million, to $800 million, and its maturity was extended to May 2028. In aggregate, ARKO currently has more than $2 billion in available capital for continued merger and acquisition activity, including cash, lines of credit, and the extended Oak Street program agreement.

07:16 EDT Societal CDMO selected by Xequel Bio to provide CDMO services - Societal CDMO announced that it has been selected by Xequel Bio to provide contract development and manufacturing organization, CDMO, services to support the ongoing clinical development of a patented new chemical entity based on its aCT1 platform. The agreement spans a range of Societal CDMO's offerings including process development and clinical trial services, culminating in cGMP manufacturing of the compound and placebo for upcoming Phase 2 clinical trials of iNexin. iNexin is a sterile, preservative-free ophthalmic solution containing aCT1 peptide that is currently being evaluated by Xequel for the potential treatment of persistent corneal epithelial defects. "We are pleased to have been selected by Xequel to continue our support of this important investigational drug candidate in the ophthalmology space. It is gratifying to be able to grow this relationship in lockstep with the advancement of iNexin into the next phase of its clinical development, demonstrating our ability to meet the evolving needs of our customers as they mature their development pipelines," said David Enloe, chief executive officer of Societal CDMO. "This new agreement is the latest highlight in what has been an active period for our business development, project management, and operations teams. In just the past six weeks, we have announced new customer agreements with Longboard Pharmaceuticals and Xequel, project expansion agreements with several existing customers, and an approval from FDA for manufacturing of a commercial tablet at our Georgia facility. We continue to deliver against our growth strategy and look forward to maintaining the momentum as we move through 2023."

07:14 EDT Bitfarms marks 21,000th bitcoin mined using renewable energy - Bitfarms announces that in six years of operations it has mined 21,000 BTC with renewable hydropower. "On May 7th, 2023, Bitfarms achieved an important milestone by producing its 21,000th BTC mined with renewable power, representing 1/1,000 of all BTC to ever be mined," said Geoff Morphy, CEO of Bitfarms. "Leading the industry, this accomplishment is a testament to the proven capabilities of our mining operations that have powered on average between 1% and 2% of the BTC network, and we are proud to have done so with sustainable hydropower. Morphy continued, "Bitfarms recognized early on the advantages of hydropower as a renewable energy resource and its sustainable and consistent economics. Our hydropower contracts provide a low direct cost of production and deliver higher mining margins than if we prioritized exahash growth alone. Bitfarms strategic expansions into Washington state and Paraguay are similar to our initial operations in Quebec, as we take advantage of excess hydropower infrastructure that became available with the migration of heavy industry. We have harnessed sustainable power with favorable economics for our shareholders, while simultaneously revitalizing communities with new jobs, capital investment, incremental tax revenues, and upgrades to the local electrical infrastructure. We thank our shareholders, directors, and team members, past and present, who made this great achievement possible."

07:14 EDT Sterling Check, ID.me identify verification recognized by Kantara Initiative - ID.me and Sterling Check announced that their in-person identity verification solution has been recognized by the Kantara Initiative for meeting federal digital identity guidelines set by the National Institute of Standards and Technology, NIST. This achievement adds to ID.me's online verification methods, including 43 million Americans who have already verified with ID.me to NIST standards and can prove their identity simply by logging in. This approach improves customer experience, equity, and security. ID.me's innovative digital identity platform and Sterling's network of retail-based kiosks enable federal, state, and local US governments to now deliver omnichannel, NIST-compliant access to identity verification. "In-person verification is critical for achieving equitable access for all who need their identity verified" said Josh Peirez, CEO of Sterling. "Whether individuals are seeking access to government services or applying for a new job, Sterling and ID.me are together providing their best path forward. Partnering with ID.me to achieve IAL2 certification is an accomplishment we are very proud of and affirms Sterling's deep commitment and strong belief in our identity solutions."

07:12 EDT HF Foods says shareholders should discard proxy materials from Raymond Ni - HF Foods Group commented on the filing of a preliminary proxy statement on behalf of the Irrevocable Trust for Raymond Ni, Weihui Kwok and Yuanyuan Wu and a related Schedule 13D/A with the U.S. Securities and Exchange Commission on May 5, 2023. The company said, "The two filings by Raymond Ni contain various material misstatements, inaccuracies, and omissions, and reflect a fundamental misunderstanding of Delaware corporate law. Among other things, Raymond Ni's preliminary proxy statement purports to support the election of five individuals as directors at the upcoming combined 2022 & 2023 Annual Meeting of Stockholders of HF Foods, none of whom are valid nominees for election to the Board of Directors of the Company for consideration at the Annual Meeting. As previously announced, the deadline for stockholders to make a valid proposal or director nomination for consideration at the Annual Meeting was Monday, April 10, 2023. Raymond Ni's nomination submission materials, which were first submitted on such date, were materially defective, and as such were invalid, under the Company's bylaws. The nominating stockholders were informed of this determination on April 11, 2023, and have not challenged or contested that determination publicly or privately with the Company before Raymond Ni's recent filing of the preliminary proxy statement and related Schedule 13D/A. Accordingly, the only proper business before the Annual Meeting, which is scheduled for Thursday, June 1, 2023, at 12:00 p.m., Eastern Time, is as set out in the Company's Notice of Annual Meeting of Stockholders and Proxy Statement, dated April 28, 2023. The Company filed the Proxy Statement with the SEC on April 28, 2023, and began mailing copies of the Proxy Statement to stockholders on or around such date. Stockholders should disregard any statements and materials that purport to add, or solicit votes for, additional director nominations or other business to be acted upon at the Annual Meeting that is not currently included in the Company's Notice of Annual Meeting, which is included in the Proxy Statement. HF Foods wishes to make clear that the Raymond Ni proxy statement and any related materials, including proxy cards, are not valid under Delaware law for use at the Annual Meeting, and cannot be used to solicit proxies in connection with the Annual Meeting and should be immediately discarded by stockholders. The Company looks forward to the participation of stockholders at the Annual Meeting. HF Foods encourages stockholders to vote by proxy or attend the Annual Meeting virtually, as further described in the Proxy Statement, to ensure that your vote is received and counted."

07:11 EDT Bruker closes acquisition of Zontal to advance digital lab 'transformation' - Bruker announced that is has closed the acquisition of ZONTAL This acquisition further strengthens Bruker BioSpin's Integrated Data Solutions IDS software division, which includes Mestrelab Research , Arxspan and Optimal . The ZONTAL acquisition will enable integrated digital laboratory and process data management, combining vendor-agnostic data storage and analysis, as well as workflow tools to help scientists realize the full potential of their analytical laboratory and process digital assets. Financial terms of the acquisition were not disclosed, and ZONTAL expects 2023 revenues of greater than $5M.

07:10 EDT BioRestorative, Northwell Heatlh enter agreement for Phase 2 trial of BRTX-100 - BioRestorative Therapies announced that it has signed a clinical trial agreement with Northwell Health, New York State's largest health care provider and private employer, and Northwell's Feinstein Institutes for Medical Research. The signing of the agreement will allow Northwell Health to participate in BioRestorative Therapies ongoing Phase 2 clinical trial targeting chronic lumber disc disease. BRTX-100, the Company's lead clinical candidate, is a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. BRTX-100 is currently being evaluated in connection with a Phase 2 clinical trial to treat cLDD. The BRTX-100 approach involves an office based injection procedure which introduces the patient's own cells which have been uniquely expanded and conditioned to result in therapeutic impact within the harsh environment of the intervertebral disc and for an all too common pain which is otherwise not reliably treated. The trial is prospective, randomized, double-blinded and controlled. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 clinical sites in the United States to receive either the investigational drug or control in a 2:1 fashion. BioRestorative recently completed enrollment for the safety run-in phase of its Phase 2 trial. Lance Alstodt, Chief Executive Officer of BioRestorative, stated, "Partnering with Northwell Health and Northwell's Feinstein Institutes for Medical Research, the largest hospital system and health provider in New York State, is a testament to the strength of our corporate profile, our technology and the prospects for our product candidate, BRTX 100. We are delighted to enter into such an agreement with Northwell and their world class team of non-surgical and surgical spine clinicians and researchers across the disciplines. We hope to identify other areas where our two organizations can work closely with one another. Research is a very obvious area of focus for both of us and we look forward to exploring strategic possibilities to enhance and strengthen our relationship with Northwell."

07:09 EDT 23andMe appoints Afkhami as Chief Corporate Development Officer - 23andMe announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. Before joining 23andMe, Afkhami was Senior Vice President of Corporate Development and Strategy at Global Blood Therapeutics, a clinical-stage biopharmaceutical company focused on innovative therapies for the treatment of sickle cell disease.

07:08 EDT BioXcel Therapeutics announces upcoming milestones - Top-line Clinical Trial Data Readouts: Pivotal SERENITY III Phase 3 trial: May 2023; Phase 1b MAD trial for MDD program: May 2023; Pivotal TRANQUILITY II Phase 3 trial: June 2023. Expected Clinical Trial Initiations: Pivotal SERENITY III Phase 3 trial: Q2 2023; Phase 2b potential pivotal study of BXCL701 in SCNC: 2H 2023

07:07 EDT Acorda and Chance in pact to commercialize Inbrija in China to treat PD - Acorda Therapeutics and Hangzhou Chance Pharmaceuticals announced that they have entered into distribution and supply agreements to provide INBRIJA in China. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease PD treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive an up-front payment of $2.5M, a near term milestone payment of up to $6M, $3M upon regulatory approval, up to $132.5M in sales milestones, and a fixed fee for each carton of INBRIJA supplied to Chance. By 2030, it is estimated that China will have approximately 5 million people with Parkinson's disease due to its aging population. Chance plans to seek regulatory authorization as quickly as possible..."Our agreement with Chance is an important milestone toward providing INBRIJA to the world's largest population of people with Parkinson's. The Chance team are experts in inhalation technologies, and we look forward to working with them to achieve regulatory approval and to provide this important medication in China," said Ron Cohen, M.D., President and CEO of Acorda Therapeutics.

07:03 EDT Ginkgo Bioworks partners with Boehringer Ingelheim - Ginkgo Bioworks announced a new partnership with Boehringer Ingelheim. The two companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery. Ginkgo and Boehringer Ingelheim will collaborate to mine Ginkgo's metagenomic sequence database, which provides access to a vast reservoir of structurally novel bioactive molecules, potentially enabling the rapid identification of lead molecules as starting points for the potential discovery of novel treatments to transform patients' lives. Under the terms of the partnership Ginkgo will receive upfront research fees and is eligible to receive success-based research and development, regulatory, and commercial milestone payments for a specified number of projects up to an aggregate total of $406M. Ginkgo is also entitled to potential further downstream value in the form of royalties on sales.

06:56 EDT Qualcomm to acquire Autotalks, terms not disclosed - Qualcomm Incorporated announced that its subsidiary, Qualcomm Technologies has entered into a definitive agreement to acquire Autotalks. The transaction is subject to customary closing conditions. The company said, "The automotive industry continues to evolve at an unprecedented rate, driven by innovation and digital technologies. Connectivity continues to play a pivotal role in the automotive industry's digital transformation as it lays the foundation for next generation software-defined vehicles that will enable new business models while transforming the driving experience with new services, personalization and most importantly, safety. Designed to enable vehicles to communicate with one another and to their surrounding environment, vehicle-to-everything communication technologies play an increasingly important role as they become critical sensors for automotive safety systems." Autotalks is a fabless semiconductor company that has been dedicated to V2X communications since 2009. The company provides automotive qualified dual-mode global V2X solutions compatible with multiple V2X standards that are designed to reduce collisions and improve mobility. The company said, "The combination of Autotalks' expertise and industry-leading products with Qualcomm's 20 years of automotive industry experience and commitment to V2X aims to help accelerate the development and adoption of V2X solutions to improve traffic efficiency and help with driver and road user safety." Through the acquisition, the production-ready, dual mode, Autotalks standalone safety solutions will be incorporated into Qualcomm Technologies' expanding Snapdragon Digital Chassis product portfolio, the company's comprehensive set of cloud-connected automotive platforms. Reference Link

06:49 EDT Enbridge announces Patrick Murray to succeed Vern Yu as CFO - Enbridge announced the following executive leadership changes. The Enbridge board of directors has appointed Patrick Murray, currently senior VP and chief accounting officer, to succeed Vern Yu as executive VP and CFO effective July 1. This appointment follows the decision by Yu, executive VP, corporate development, CFO and president, New Energy Technologies to leave the company on June 30 in conjunction with his appointment as president and CEO of AltaGas. Murray joined Enbridge in 1997 and has held a number of positions of increasing responsibility within the Finance group. He was appointed Senior Vice President & Chief Accounting Officer of Enbridge in 2020 and previously served as Vice President, Financial Planning, Analysis & Controller from 2018-2020, as Vice President, Financial Planning & Analysis from 2017 to 2018 and as Vice President, Treasury from 2014 to 2017. Mr. Murray is a Chartered Professional Accountant and holds a Bachelor of Commerce Degree from the University of Alberta.

06:47 EDT BioNTech backs FY23 Covid-19 vaccine revenue ~EUR 5B

06:18 EDT AES Corp. outlines long-term outlook - AES Corp. outlined its long-term strategy for growth, including substantial growth in renewables and US utilities, and fully exiting coal by year-end 2025. The company is initiating an annualized growth target for adjusted earnings per share of 6% to 8% through 2027, from a base of its reaffirmed 2023 guidance of $1.65 to $1.75. Growth is expected to be primarily driven by contributions from new renewables expected to come online and investments in the rate base at the Company's Utilities Strategic Business Unit, or SBU. This growth is expected to be partially offset by lower contributions from the Energy Infrastructure SBU as the company intends to exit coal by year-end 2025, asset sales, and higher Parent interest. The company is reaffirming its annualized growth target for adjusted EPS of 7% to 9% annualized growth target through 2025, from a base year of 2020. The company is including adjusted EBITDA as a financial metric to add clarity, including: exclusion of tax attributes; less influence from timing of new project commissionings; closer alignment of underlying business performance and operating cash generation and use in valuing contracted renewables portfolios. The company is initiating 2023 adjusted EBITDA guidance of $2.6B to $2.9B. Growth in 2023 is expected to be primarily driven by contributions from new renewables projects coming online, as well as prior-year one-time expenses at the company's US utilities. This growth is expected to be partially offset by lower margins from the company's LNG business, due to normalization of LNG prices and the roll-off of a gas supply contract, and lower coal margins. Annualized growth in Adjusted EBITDA is expected to be 3% to 5% through 2027, from a base of 2023 guidance. This growth is expected to be primarily driven by contributions from new renewables expected to come online and investments in the rate base at the Company's Utilities SBU, partially offset by asset sales and lower contributions from the Energy Infrastructure SBU. Excluding the company's Energy Infrastructure SBU, annualized growth in Adjusted EBITDA is expected to be 17% to 20% through 2027, from a base of 2023 guidance. The company's 2023 guidance is based on foreign currency and commodity forward curves as of March 31.

06:05 EDT Six Flags reports $5.42 increase in guest spending per capita in Q1 - The $5.42 increase in guest spending per capita compared to first quarter 2022 consisted of a $4.53 increase in Admissions spending per capita and a $0.89 increase in In-park spending per capita. The increase in guest spending per capita was driven by higher revenue from memberships beyond the initial 12-month commitment period, which is recognized evenly each month and includes a portion of revenue that is allocated to Park admissions revenue and to Park food, merchandise and other revenue. Higher membership revenue in first quarter 2023 increased Admissions spending per capita and In-park spending per capita by approximately $5 and $1, respectively, versus the prior year. Excluding this impact, Admissions spending per capita and In-park spending per capita in first quarter 2023 were essentially flat versus the prior year period. "We are pleased to have delivered record first quarter revenue and the second-highest first quarter Adjusted EBITDA in our company's history, which we believe are proof points that our new strategy and our new culture are beginning to take hold," said Selim Bassoul, President and CEO. "Looking ahead, our team is excited to launch numerous special events this summer, including Viva La Fiesta, Flavors of the World, Six Flags Fireworks Spectacular, and parades. These events, combined with exciting new rides and attractions and our focused investments in infrastructure, should help us deliver an enhanced guest experience this year. We are still in the early stages of our transformation, but with our season pass sales accelerating and our attendance improving, we are encouraged by our recent progress."

05:10 EDT Farallon comments on upcoming board candidates at Exelixis - Funds managed by Farallon Capital Management own approximately 7.2% of the outstanding shares of Exelixis, making it the company's largest active shareholder. Farallon nominated three candidates for election to the Exelixis board of directors at the upcoming annual meeting of shareholders, which will be held on May 31. Exelixis had previously agreed to support two of Farallon's nominees, Tom Heyman and Bob Oliver. Incumbent director Lance Willsey, whom Farallon had targeted for replacement on the board by Farallon's third candidate, Dave Johnson, resigned from his directorship and determined he would not stand for reelection. As a result, Dave Johnson is expected to be elected to the company's board. Farallon stated: "This election is about catalyzing change at a company that has long resisted making meaningful adjustments to its R&D priorities and capital allocation approach. With the anticipated election of all three Farallon nominees, we expect the Board to now objectively review the Company's longstanding underperformance and genuinely consider the opportunities for improvement through a more focused R&D effort. It is unfortunate that it took our engagement for the Company to initiate a share repurchase plan and our proxy contest to compel the Board to refresh its stale Board of Directors. The Board's insistence on contesting our nominees until now underscores its aversion to change. Fortunately, the Farallon candidates are positioned to bring fresh perspectives to the Board. Dave Johnson will bring current biotechnology expertise, a shareholder mindset and much-needed independence and objectivity to the boardroom. We believe he will be an exceptional addition, and together with Farallon candidates Tom Heyman and Bob Oliver, will help drive long-overdue change at Exelixis. We and our fellow shareholders must remain vigilant at Exelixis, or the Board and Company may fall back into old patterns. Exelixis has a tremendous opportunity to benefit patients and shareholders by communicating a clear strategy, focusing its R&D efforts and improving capital allocation. In order to ensure these things happen, it is essential that an unequivocal message be sent to the Company that shareholders will not accept any further foot dragging or attempts to preserve the status quo. This is why we urge shareholders to vote for all three of our candidates."